Evofem Biosciences Inc to Discuss the FDA Approval of Phexxi - Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Evofem Biosciences Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I'll now turn the call over to Amy Raskopf, Head of Investor Relations for Evofem Biosciences. Please go ahead.
Thank you, operator. Welcome, everyone, to the Evofem Biosciences conference call to discuss the FDA approval of Evofem product Phexxi. The press release we issued on Friday highlighting this important event can be accessed in the Investors section of our website at evofem.com.
Joining me on the call today are Saundra Pelletier, Evofem's Chief Executive Officer; Russ Barrans, our Chief Commercial Officer; and Jay File, our Chief Financial Officer. Our Chief Medical Officer, Dr. Kelly Culwell, will join us for the Q&A portion of this call.
As a reminder, during today's call, we will be making certain forward-looking statements, which are made only as of today, May 26, 2020. For a more
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |